Biogen Inc. (BIIB)

In July, the RMPIA climbed 0.6%, bringing its year-to-date return to just over 21%.

AbbVie and Bristol-Myers Squibb are two pharmaceutical giants where insiders have snatched up big blocks of stock.

-- Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events --

— Diroximel Fumarate Demonstrated Statistically Superior Gastrointestinal (GI) Tolerability on EVOLVE-MS-2 Study's Primary Endpoint Assessing Self-Reported GI Events — — Discontinuations Due to GI Events were Less than 1% for Diroximel Fumarate — DUBLIN,...

With a third of S&P 500 stocks having reported, these 3 trends are coming to the fore.

Be zen and keep emotions out of investing decisions. It can pay off in higher portfolio returns.

The drugmaker reports second-quarter results that beat analysts' forecasts and raises its guidance for the remainder of the year on strong demand for its multiple sclerosis and other disease-fighting medications.

U.S. stock futures rise ahead of earnings reports from a number of corporate heavyweights and after the White House and congressional negotiators reach a budget deal that will lift the government's debt limit; Coca-Cola, Snap, Visa and Harley-Davidson are among the companies reporting earnings on Tuesday; Apple reportedly is in talks to buy Intel's modem chip business for $1 billion.

Use buy-write orders as a conservative way to invest in GILD in these uneasy times.

Shares of Gilead Sciences are jumping higher on its increased investment in Galapagos and a new outperform rating from Wells Fargo.

There are a number of RMPIA companies that will be beneficiaries of Back to School and holiday spending.

- New results from the NURTURE study demonstrate that pre-symptomatic infants treated with SPINRAZA are achieving motor milestones that are unprecedented in the natural history of the disease, including 100 percent of children sitting without support and 88 percent walking independently

The firm now has a neutral rating on Biogen based on data from a new neurologist survey.

Buyers have returned in recent months and the stock could be ready to rise.

The drop in AbbVie's stock price following revelation of its plans to buy Allergan provides a way to hit a solid investment single using a buy-write options strategy.

After a five-year hiatus I'm ready to start throwing whammies in several directions.

LOS ANGELES, May 23, 2019 /PRNewswire/ -- Wedbush Securities is pleased to announce that Senior Vice President of Equity Research, Laura Chico, Ph.

WOODCLIFF LAKE, N.J.

WOODCLIFF LAKE, N.J.

RMPIA outperformed once gain during April.

What are the main takeaways from Chevron, Ford and others? Cramer explains.

Need a road map to close out this week on Wall Street? Jim Cramer breaks down everything investors need to know about the markets from Chevron to Intel.

Need a road map to close out this week on Wall Street? Jim Cramer breaks down everything investors need to know about the markets from Chevron to Intel.